RecruitingNCT00373841
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis
Sponsor
University of Pittsburgh
Enrollment
500 participants
Start Date
Oct 1, 2005
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients who are 18 or older
- Diagnosis of Idiopathic Pulmonary Fibrosis
- Treated at the Simmons Center
Exclusion Criteria1
- Other Lung Illness
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00373841
Related Trials
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622371 locations
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT0703652347 locations
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
NCT062415603 locations
Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT058426812 locations
NAL ER IPF Respiratory Function and Safety Study
NCT070360292 locations